AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Results of a phase III trial investigating the combination of Lenalidomide and Rituximab for treatment of relapsed indolent lymphomas.